Open-label, Phase 1 Study of haNK™ for Infusion in Subjects With Metastatic or Locally Advanced Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 03 Sep 2019
Price : $35 *
At a glance
- Drugs CD16 and interleukin 2 expressing natural killer cells-NantKwest (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man
- Acronyms QUILT-3.028
- Sponsors NantKwest
- 23 Aug 2019 Status changed from active, no longer recruiting to completed.
- 10 May 2019 Status changed from recruiting to active, no longer recruiting.
- 07 Nov 2018 Results published in the Media Release